OBJECTIVE: This article serves as a resource for health care professionals by providing a
summary of primary literature and guidelines for use of the available oral anticoagulant …

This study examined potential differences in bleeding between apixaban and rivaroxaban,
the most commonly utilized direct oral anticoagulants at the Richard L. Roudebush VA …

Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical
development for the prevention and treatment of thromboembolic diseases. Apixaban was …

Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an increased prevalence
in older adults. 1 The estimated lifetime risk of developing AF is one in four for both men and …

Purpose Data comparing traditional and novel anticoagulants are reviewed, and the
potential use of new oral agents for the prevention and treatment of venous …

The availability of new oral anticoagulants (NOACs) targeting either thrombin (dabigatran
etexilate) or factor Xa (rivaroxaban and apixaban) for the prevention and treatment of …

Background: Apixaban, a direct factor Xa inhibitor, is approved by the US Food and Drug
Administration (FDA) for prevention of stroke and systemic embolism in nonvalvular atrial …

Aims There are concerns regarding increased risk of acute coronary syndrome with
dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban …

Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for
many decades. Although effective, warfarin has numerous limitations, including a variable …

Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …